China blueprints drug-safety improvements

Chinese officials rolled out a plan to improve drug standards and monitoring over the next 5 years, saying "[m]edicinal safety is in a high-risk stage." Among the goals are stepped-up monitoring of adverse events, a credit-rating system, post-marketing surveillance and severe punishments for counterfeiters and misbehaving drug executives. Report

Suggested Articles

Allergan was willing to part with candidate brazikumab to pass FTC muster, but union and consumer groups say that sale won't amend antitrust worries.

North Carolina is providing some financial assistance for the construction of Audentes gene therapy facility in Sanford, North Carolina. (Astellas)

BMS' Opdivo-Yervoy combo is playing in an increasingly crowded space. But the company is leaning on new long-term data to set its regimen apart.